<li>astemizole<p>verapamil increases levels of astemizole by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>cisapride<p>verapamil increases levels of cisapride by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>dantrolene<p>dantrolene, verapamil.
Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Contraindicated. Rare incidence of cardiovascular collapse and marked hyperkalemia observed when coadministered; may be higher risk with nondihydropyridine calcium channel blockers.</p></li><li>flibanserin<p>verapamil will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur.</p></li><li>lomitapide<p>verapamil increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increases lomitapide levels several folds.</p></li><li>pimozide<p>verapamil increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>terfenadine<p>verapamil increases levels of terfenadine by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li>